PERSPECTIVE THERAPEUTICS, INC. (CATX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -125.23M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 96.18M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-125.23M | (m) | (m) | $96.18M | (m) | (m) |
| 2026-03-31 | $-120.01M | (m) | (m) | $91.25M | (m) | (m) |
| 2025-12-31 | $-113.56M | (m) | (m) | $84.22M | (m) | (m) |
| 2025-09-30 | $-118.72M | (m) | (m) | $64.17M | (m) | (m) |
| 2025-06-30 | $-109.49M | (m) | (m) | $55.86M | (m) | (m) |
| 2025-03-31 | $-99.71M | (m) | (m) | $48.52M | (m) | (m) |
| 2024-12-31 | $-90.89M | (m) | (m) | $41.64M | (m) | (m) |
| 2024-09-30 | $-57.58M | (m) | (m) | $35.84M | (m) | (m) |
| 2024-06-30 | $-48.69M | (m) | (m) | $29.36M | (m) | (m) |
| 2024-03-31 | $-44.19M | (m) | (m) | $25.45M | (m) | (m) |
| 2023-12-31 | $-40.94M | (m) | (m) | $21.31M | (m) | (m) |
| 2023-09-30 | $-36.82M | (m) | $6.29M | $15.82M | (m) | (m) |
| 2023-06-30 | $-30.50M | (m) | $6.15M | $10.81M | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-11.38M | (m) | $5.78M | $2.65M | (m) | (m) |
| 2022-09-30 | $-9.32M | (m) | $5.95M | $2.59M | (m) | (m) |
| 2022-06-30 | $-7.39M | $10.79M | $6.18M | $2.58M | (m) | -68.47% |
| 2022-03-31 | $-6.38M | (m) | $5.96M | $2.25M | (m) | (m) |
| 2021-12-31 | $-5.77M | (m) | $5.73M | $2.07M | (m) | (m) |
| 2021-09-30 | $-5.01M | (m) | $5.33M | $1.82M | (m) | (m) |
| 2021-06-30 | $-3.45M | $10.05M | $4.93M | $1.43M | (m) | -34.28% |
| 2021-03-31 | $-3.54M | (m) | $4.78M | $1.28M | (m) | (m) |
| 2020-12-31 | $-3.32M | (m) | $4.71M | $1.21M | (m) | (m) |
| 2020-09-30 | $-3.35M | (m) | $4.62M | $1.21M | (m) | (m) |
| 2020-06-30 | $-3.48M | $9.68M | $4.56M | $1.13M | (m) | -35.91% |
| 2020-03-31 | $-3.43M | (m) | $4.39M | $1.15M | (m) | (m) |
| 2019-12-31 | $-4.05M | (m) | $4.26M | $1.15M | (m) | (m) |
| 2019-09-30 | $-4.57M | (m) | $4.31M | $1.29M | (m) | (m) |
| 2019-06-30 | $-5.25M | $7.31M | $4.27M | $1.47M | (m) | -71.83% |
| 2019-03-31 | $-6.48M | (m) | $4.39M | $1.71M | (m) | (m) |
| 2018-12-31 | $-6.66M | $6.64M | $4.31M | $1.88M | (m) | -100.21% |
| 2018-09-30 | $-6.70M | $6.27M | $4.17M | $1.80M | (m) | -106.71% |
| 2018-06-30 | $-6.73M | $5.92M | $4.08M | $1.75M | (m) | -113.61% |
| 2018-03-31 | $-6.22M | (m) | (m) | $1.49M | (m) | (m) |
| 2017-12-31 | $-6.27M | (m) | (m) | $1.34M | (m) | (m) |
| 2017-09-30 | $-6.28M | (m) | (m) | $1.16M | (m) | (m) |
| 2017-06-30 | $-6.31M | (m) | (m) | $965.00K | (m) | (m) |
| 2017-03-31 | $-5.70M | (m) | (m) | $792.05K | (m) | (m) |
| 2016-12-31 | $-5.64M | (m) | (m) | $648.05K | (m) | (m) |
| 2016-09-30 | $-5.57M | (m) | (m) | $556.05K | (m) | (m) |
| 2016-06-30 | $-5.08M | (m) | (m) | $528.05K | (m) | (m) |
| 2016-03-31 | $-4.93M | (m) | (m) | $541.46K | (m) | (m) |
| 2015-12-31 | $-4.66M | (m) | (m) | $499.67K | (m) | (m) |
| 2015-09-30 | $-4.27M | (m) | (m) | $582.06K | (m) | (m) |
| 2015-06-30 | $-4.34M | (m) | (m) | $614.77K | (m) | (m) |
| 2015-03-31 | $-4.55M | (m) | (m) | $656.81K | (m) | (m) |
| 2014-12-31 | $-4.49M | (m) | (m) | $669.02K | (m) | (m) |
| 2014-09-30 | $-4.51M | (m) | (m) | $698.42K | (m) | (m) |
| 2014-06-30 | $-4.59M | (m) | (m) | $668.80K | (m) | (m) |
| 2014-03-31 | $-4.29M | (m) | (m) | $651.95K | (m) | (m) |
| 2013-12-31 | $-4.12M | (m) | (m) | $653.48K | (m) | (m) |
| 2013-09-30 | $-4.18M | (m) | (m) | $632.63K | (m) | (m) |
| 2013-06-30 | $-4.07M | (m) | (m) | $627.11K | (m) | (m) |
| 2013-03-31 | $-3.99M | (m) | (m) | $653.15K | (m) | (m) |
| 2012-12-31 | $-3.93M | (m) | (m) | $630.25K | (m) | (m) |
| 2012-09-30 | $-3.62M | (m) | (m) | $670.74K | (m) | (m) |
| 2012-06-30 | $-3.60M | (m) | (m) | $780.58K | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | $-2.96M | (m) | (m) | $981.19K | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |